View Post

HSV Treatment Readies for Approval

In COVID-19, Latest News by Precision Vaccinations

A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV).
As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of herpes, HSV-1 and HSV-2.
Published on March 1, 2023, a peer-reviewed study disclosed Pritelivir was evaluated in five phase 1 trials, a single-ascending-dose trial, two multiple-ascending-dose trials, and others.

View Post

Nets Treated with Pyrethroid-Chlorfenapy Recommended During Malaria Outbreaks

In Travel Vaccine News by Travel Vaccine

The World Health Organization (WHO) recently updated its malaria policy guidelines to recommend using long-lasting insecticidal nets (LLINs)  treated with a combination of insecticides, which researchers say could be a game-changer in the global fight against the disease if managed effectively.
The WHO now recommends that malaria-endemic regions experiencing pyrethroid resistance switch to the more effective pyrethroid-chlorfenapyr nets.

View Post

New Dengue Vaccine Pricing Disclosed

In COVID-19, Latest News by Precision Vaccinations

As the new tetravalent dengue fever vaccine from Takeda Pharmaceutical Company rapidly gains approvals around the globe, many interested parties were asking what this innovative disease protection would cost.
'We aim to make QDENGA® available to all eligible for vaccination in the countries where approved,' stated Takeda's presentation led by Ramona Sequeira, President, Global Portfolio Division, on March 15, 2023.
For example, Takeda disclosed these classifications: